Compare
Metagenomi Therapeutics, Inc. vs Alector, Inc. vs Scilex Holding Co vs LENZ Therapeutics, Inc.
| Latest fiscal year | Metagenomi Therapeutics, Inc. MGX | Alector, Inc. ALEC | Scilex Holding Co SCLXRevenue covers only part of its income (partial revenue) | LENZ Therapeutics, Inc. LENZ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $25.21M | $21.05M | $30.25M | $19.09M |
| Revenue growth (YoY) | -51.8% | -79.1% | -46.5% | n/a |
| Gross margin | n/a | n/a | 65.0% (computed) | n/a |
| Operating margin | -380.9% | -741.3% | n/m | -477.5% |
| Net margin | -348.5% | -679.2% | n/m | -430.3% |
| Net income | -$87.87M | -$142.93M | -$374.05M | -$82.13M |
| EPS (Diluted) | -$2.36 | -$1.39 | -$36.48 | -$2.85 |
| Operating cash flow | -$88.89M | -$184.03M | $3.82M | -$69.17M |
| Free cash flow | -$89.47M | -$184.07M | $3.68M | -$70.00M |
| Cash & equivalents | $41.72M | $65.80M | $4.96M | $25.18M |
| Total assets | $221.10M | $293.24M | $364.98M | $305.88M |
| Total liabilities | $62.51M | $262.59M | $576.73M | $21.54M |
| Shareholders' equity | $158.60M | $30.65M | -$207.78M | $284.34M |
| Return on year-end equity | -55.4% | -466.3% | n/a | -28.9% |
| Shares outstanding | 37.62M | 110.36M | 7.03M | 31.34M |
Revenue, most recent five fiscal years
| Fiscal year | Metagenomi Therapeutics, Inc. | Alector, Inc. | Scilex Holding Co | LENZ Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $25.21M Ended 2025-12-31 | $21.05M Ended 2025-12-31 | n/a | $19.09M Ended 2025-12-31 |
| 1 year earlier | $52.30M Ended 2024-12-31 | $100.56M Ended 2024-12-31 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | $44.76M Ended 2023-12-31 | $97.06M Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | n/a | $133.62M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $207.09M Ended 2021-12-31 | n/a | n/a |